IDH1 and glioblastoma: IDH wild-type patients with GBM with PDGFRA gain/amplification and unmethylated MGMTp were assigned to the poor-prognosis group, whereas those harboring either PDGFRA gain/amplification or unmethylated MGMTp were assigned to the intermediate-prognosis group.